The Progression of Celiac Disease, Diagnostic Modalities, and Treatment Options

Zahid Ijaz Tarar, MD1, Muhammad Usman Zafar, MD2, Umer Farooq, MD3, Omer Basar, MD1, Veysel Tahan, MD1, and Ebubekir Dagililar, MD1

Abstract
Celiac disease (CD) is an autoimmune disorder that affects genetically predisposed individuals who are sensitive to gluten and related proteins. It affects children and adults with increasing prevalence in the older age groups. Both adaptive and innate immune responses play role in CD pathogenesis which results in damage of lamina propria and deposition of intraepithelial lymphocytes. There are other proposed mechanisms of CD pathogenesis like gastrointestinal infections, intestinal microbiota, and early introduction of gluten. The diagnosis of CD is based on clinical symptoms and serological testing, though a majority of cases are asymptomatic, and small intestinal biopsies are required to confirm the diagnosis. Celiac disease is generally associated with other autoimmune diseases, and it is advisable to test these patients for diseases like type 1 diabetes mellitus, Addison’s disease, thyroid diseases, inflammatory bowel disease, and autoimmune hepatitis. The patient with a new diagnosis of CD requires close follow-up after starting treatment to see symptom improvement and check dietary compliance. A newly diagnosed patient is advised to follow with a dietitian to better understand the dietary restrictions as about 20% of patients stay symptomatic even after starting treatment due to noncompliance or poor understanding of diet restrictions. The most effective treatment for CD is a gluten-free diet, but work on non-dietary therapy is in process and few medications are in the clinical trial phase.

Keywords
celiac disease, small intestinal biopsy, autoimmune diseases, serology, gluten, diet, therapy, treatment

Introduction
Celiac disease (CD) is an immune-mediated disorder affecting small intestine in genetically predisposed individuals. It results from sensitivity to gluten and related proteins.1,2 The global prevalence of CD is 1%3,4 though it does not represent the actual number of CD cases due to the vast majority of cases are asymptomatic and undiagnosed as reported in different studies. One study done in Italy showed 7:1 ratio of asymptomatic to symptomatic cases,5 which is further reinforced by studies in which antibody testing performed for screening purposes.6-9 Celiac disease is more prevalent in first- and second-degree relatives and people with other autoimmune disorders.8,10

Celiac disease results from an abnormal response to gluten which causes small intestinal injury and leads to malabsorption of nutrients. Celiac disease prevalence has increased 4 to 5 times in the last few decades, and the average age of diagnosis is the fifth decade of life in the United States.11,12 CD has 2 peaks of onset, one in early childhood around age of 2 years and the second in second to third decade of life.13,14 As per Oslo’s 2011 definition, CD can be classified as classic, non-classic, subclinical, silent, overt, potential, and refractory.15,16 The other way of classifying CD is based on location and histological appearance. Based on location, it can be categorized as intestinal vs extraintestinal or a combination of both.17

1University of Missouri, Columbia, USA
2Lehigh Valley Health Network, Allentown, PA, USA
3Loyola Medicine/MacNeal Hospital, Berwyn, IL, USA

Received August 11, 2021. Revised September 20, 2021. Accepted September 28, 2021.

Corresponding Author:
Zahid Ijaz Tarar, MD, Department of Internal Medicine, University of Missouri, One Hospital Drive, Columbia, MO 65212, USA.
Email: drzahidejaz@hotmail.com
Histologically, CD was classified by Marsh and was later modified by Marsh-Oberhuber in 1999 (Table 1). Corazza proposed another classification but not widely accepted. Modified Marsh classification is the recommended histological classification by the Gastroenterology association but still not used widely.\textsuperscript{18-20}

### Pathogenesis

Celiac disease is an autoimmune disease affecting the genetically predisposed individuals in the setting of environmental trigger.\textsuperscript{21} It results from abnormal T-cell response to gluten, which is found in cereal grain wheat, rye, and barley.\textsuperscript{21,22} In genetically predisposed individuals, exposure to gliadin peptide which is a component of gluten leads to an adaptive immune response that causes damage to lamina propria.\textsuperscript{23-26} In addition to adaptive response, innate immune response is the other factor which plays an important part in CD pathogenesis which can be seen by the presence of intraepithelial lymphocytes.\textsuperscript{26,27} Celiac disease is common in families which is evident by the presence of specific HLA types HLA-DQ2 and HLA-DQ8 in almost all cases.\textsuperscript{28,29} The intestinal microbiota is also considered another factor in the pathogenesis of CD leading to an immune response in addition to gluten and other environmental factors and this is shown in few studies.\textsuperscript{30-34} Other factors considered and discussed in literature about CD pathogenesis are a shorter duration of breastfeeding, infections, and early introduction of gluten, but these are not proven with studies.\textsuperscript{35,36} On the contrary, the adult populations rarely have the classic malabsorption symptoms, and they usually present with irritable bowel syndrome-like symptoms in association with nausea and vomiting, and the reason for their hospitalization is mainly electrolyte imbalance and cachexia.\textsuperscript{44-46}

Celiac disease in its classic form presents with gastrointestinal malabsorption symptoms, but we need to be careful in diagnosing as about 40% of patients with CD are obese at diagnosis and constipation can be presenting symptom in 20% of patients.\textsuperscript{15,16,47,48} Another rare presentation is the celiac crisis which presents as diarrhea and shows severe electrolyte disturbances.\textsuperscript{48} In the past, majority of diagnosed cases were of symptomatic disease but now the non-classic and subclinical forms are increasingly diagnosed but the classic form is still the most common presenting type and makes about half of the diagnosed cases.\textsuperscript{15,45}

Celiac disease is now seen more frequently in adults and older population, and the reason for this is better diagnosis

### Clinical Subtypes of CD

Celiac disease is clinically defined as classic, non-classic, subclinical, potential, and refractory.\textsuperscript{16} Classic CD, however, affects both pediatric and adult population but mainly diagnosed between 6 and 18 months of age and presents with typical symptoms of malabsorption including diarrhea, failure to thrive, and weight loss. The atypical or non-classic form mainly present as extraintestinal manifestation of CD such as osteoporosis, abnormal liver function, vitamin deficiencies, anemia, neuropathy, or infertility, but patients with atypical disease can have gastrointestinal symptoms like reflux, bloating, or abdominal pain. The atypical form is usually diagnosed in high-risk population on screening. Subclinical form of CD also falls under atypical disease. Latent or potential form of CD is defined as normal small bowel architecture but positive serology and presence of HLA-DQ2 and/or HLA-DQ8. Refractory CD is the presence of symptoms even after strict dietary restriction for 6 to 12 months.\textsuperscript{39,40}

### Clinical Manifestations

Celiac disease is more common in females with F:M ratio of 2:1, and females are usually diagnosed at a young age with predominant symptoms of constipation and iron deficiency anemia.\textsuperscript{13,15,41} Celiac disease diagnosis is challenging as the majority of patients are asymptomatic and the ones with symptoms vary significantly.\textsuperscript{42} The symptomatic patients can have gastrointestinal symptoms in combination with extraintestinal manifestation or they can just present with extraintestinal symptoms.\textsuperscript{17} Gastrointestinal symptoms like diarrhea, loss of appetite, malabsorption, failure to thrive, short stature, and delayed puberty are mainly seen in the pediatric population.\textsuperscript{16,43}

#### Table 1. Modified Histological Classification of Celiac Disease.

| Type | Intraepithelial lymphocytes/100 enterocytes | Crypt hyperplasia | Villi |
|------|-----------------------------|-----------------|------|
| 0    | <40                         | Normal          | Normal|
| 1    | >40                         | Normal          | Normal|
| 2    | >40                         | Increased       | Normal|
| 3a   | >40                         | Increased       | Mild atrophy|
| 3b   | >40                         | Increased       | Moderate atrophy|
| 3c   | >40                         | Increased       | Complete atrophy|
tools and understanding of the disease, although in most cases the disease is mild in this age group and the main presenting symptoms are nutrient deficiencies and iron deficiency anemia.\textsuperscript{15,49}

Celiac disease is a multi-organ system disease, and few studies showed extraintestinal symptoms as the most common presentation.\textsuperscript{15,45} Extraintestinal symptoms are seen in both children and adults and osteoporosis is the most common with a frequency of about 70% due to changes in calcium and vitamin D absorption.\textsuperscript{44,45,50} Patients with severe osteoporosis and bone loss especially if they are young males should be worked up for CD even in the absence of gastrointestinal symptoms.\textsuperscript{51} Bone disease is the main cause of morbidity in patients with CD and increases the fracture risk significantly as compared with the general population.\textsuperscript{51,52}

The second most common presentation is iron deficiency anemia which is seen in about 40% of cases secondary to inflammation and malabsorption of iron and commonly seen in newly diagnosed patients.\textsuperscript{53,54} Other common manifestations are neurological symptoms such as headache, paresthesia, cerebellar ataxia, myoclonic syndrome, epilepsy with cerebral calcifications, anxiety, and depression, and it is associated with elevated levels of anti-gliadin antibodies.\textsuperscript{45,55-57}

Celiac disease affects the reproductive system in both males and females, so patients can present with unexplained infertility, recurrent abortions, miscarriages, early menopause, late menarche, or abnormality of sperms, and these changes are reversible with a gluten-free diet, so these cases need high suspicion and need a workup for CD even in the absence of malabsorption symptoms.\textsuperscript{43,58-62} Undiagnosed pregnant cases of CD can lead to premature and small for gestational age babies.\textsuperscript{61,63}

Other common extraintestinal manifestations of CD are abnormal liver tests known as celiac liver,\textsuperscript{64,65} hyposplenism,\textsuperscript{66} dermatitis herpetiformis,\textsuperscript{45,67,68} aphthous ulcer,\textsuperscript{45,69} dental enamel hypoplasia,\textsuperscript{70} and acute and chronic pancreatitis.\textsuperscript{71}

**Diagnosis**

The mainstay of CD diagnosis is based on clinical features in combination with serology testing and histological findings. Antibodies used for CD diagnosis are anti-tissue transglutaminase (anti-tTG), anti-endomysium, and deamidated gliadin peptide (DGP). The preferred single test is anti-tTG antibodies with a sensitivity of 93% and specificity of 94%. Although the anti-endomysial antibody test is most specific than all other serological tests, it is a qualitative test, operator dependent, and difficult to perform.\textsuperscript{72-76} Studies done on DGP, in the beginning, were promising about its role in the diagnosis of CD, but over the course, data showed a decrease in its specificity, so now IgG-DGP is sometimes used for diagnosis in children aged <2 years but DGP-IgA lacks accuracy and not used in current practice.\textsuperscript{72,77,78} To increase the sensitivity of serological testing, British society of Gastroenterology recommends sequential testing with tTG-IgA and DGP-IgG.\textsuperscript{79} Even with the advancement in serology testing and easy availability still, none of these tests are 100% sensitive or specific which makes intestinal biopsy an important component for the diagnosis.\textsuperscript{80,81}

The best method to establish the diagnosis is based on the “4 out of 5 rule,” in which 4 out of these 5 criteria need to be present to diagnose someone with CD. These include classic signs and symptoms, antibody positivity, HLA-DQ2 and/or HLA-DQ8 positivity, intestinal damage, and clinical response to the gluten-free diet.\textsuperscript{81} The current guidelines for the diagnosis of CD are based on case findings in which all populations with high risk need to be tested, but this is not proven beneficial and U.S Preventive service Task Force (USPSTF) has recommended against it.\textsuperscript{75,79,82,83} In the pediatric population, intestinal biopsy can be avoided if a child has typical symptoms and signs of CD in combination with high titers of anti-tTG, detectable endomysial antibody, and HLA-DQ2/HLA DQ8 positivity, as recommended by the European Society for Pediatric Gastroenterology Hepatology and Nutrition,\textsuperscript{84,85} but these criteria are not used worldwide,\textsuperscript{86} so biopsy is still needed in the majority of the pediatric and almost all adult cases to establish the diagnosis.

Endoscopy with small intestinal biopsy is the gold standard test in adult patients and mandatory for establishing the diagnosis of CD.\textsuperscript{86} Endoscopists need to be vigilant while taking duodenal biopsies as CD results in patchy mucosal changes, mainly involve the proximal intestine, with only 10% of cases will show changes in the duodenal bulb. So during endoscopy, at least 4 to 6 biopsies, out of which 2 from duodenal bulb and 4 from second part of the duodenum is needed for accurate diagnosis.\textsuperscript{14,87} Celiac disease lesions can be differentiated into 5 stages based on histology as defined by Marsh and later modified by Oberhuber.\textsuperscript{20} But studies have shown these systems are not used widely by pathologists due to disagreement on grading, so a more uniform grading system is needed.\textsuperscript{88}

There are certain conditions like enteric infection, congestive heart failure, and a chronic liver disease which can lead to false-positive results due to cross-reactivity of antibodies.\textsuperscript{89} On the contrary, patients need to be on a gluten-containing diet “gluten challenge” (>3 g gluten/day for at least 2 weeks) before getting tested, otherwise, there are chances for false-negative results.\textsuperscript{75,89,90} A patient with CD has a higher prevalence of IgA deficiency as compared to the general population which is another reason for false-negative results, so in IgA-deficient patient anti-DGP IgG antibodies or tTG-IgG antibodies should be performed.\textsuperscript{75,91}

There are cases in which serology is negative, but antigen haplotype DQ2 and or /DQ8 and histological changes like villous atrophy are present, this is called seronegative CD and it can result from strong antigen-antibody complexes deposition in mucosa which leads to decreased antibody entry into circulation.\textsuperscript{91,93}

HLA typing is a good way of ruling out CD, but it cannot be used for the diagnosis.\textsuperscript{84} HLA typing is used for the
diagnosis of seronegative CD as well as a screening tool for seronegative first-degree relative of a patient with CD.84,94

The presence of low hemoglobin, elevated transaminases, and bone-specific alkaline phosphatase on routine blood work can provide clues about CD diagnosis. Iron deficiency is one of the most common extraintestinal manifestations, though you can also see normocytic or macrocytic anemia due to malabsorption of vitamin B12 and folic acid in CD.53,98-97

Treatment

At present, the main and only effective treatment for CD is a gluten-free diet for life and strict avoidance of wheat, barley, and rye is needed.46,98,99 Strict adherence to gluten-free diet results in resolution of symptoms within days to weeks, negative serology, and normalization of villous atrophy.47,100 Although a gluten-free diet is very effective in treating CD, it still comes with many disadvantages, including high cost, nutrient and mineral deficiencies, psychological impact, constipation, and cardiovascular disease risk.100-103 To avoid these negative effects of a gluten-free diet, it is recommended to have a regular follow-up with a trained dietitian who carries expertise in treating patients with CD.104,105 One main reason for non-adherence to a gluten-free diet is wrong online information about gluten products, cross-contamination, presence of a small amount of gluten in medications, social pressure in adolescence, and for all these reasons close follow-up with dietitian and enrollment in a CD support group is recommended.106-109

Nonresponsive and Refractory CD

There are about 20% of patients in which diarrhea, abdominal pain, and fatigue persist even after starting a gluten-free diet and in these cases either the initial diagnosis of CD was made wrong or the patient is non-compliant with a gluten-free diet or gluten contamination.110-113 So in the cases of deliberate gluten ingestion or food contamination, a dietitian referral is recommended to get more information about the gluten-free diet and possible contamination.111 Persistent symptoms after 12 months of treatment can be due to other conditions like microscopic colitis, irritable bowel syndrome, and lactose intolerance, so for that reason, duodenal biopsies and colon biopsies are recommended to find the actual cause of symptoms.110,113,114 In few patients, even after strictly following the diet restriction for 12 months, symptoms and villous atrophy persist labeled as refractory CD. The refractory CD has 2 subtypes and duodenal biopsies are required to look for aberrant T-cell population found in type 2 which is severe form and associated with worse outcomes.115-117 Refractory CD type 1 is treated with steroids or azathioprine in combination with steroids, open-capsule budesonide, and aggressive nutrition is commonly used as first-line therapy. There is no agreement on the treatment of refractory CD type 2, although steroids, cyclosporine, cladribine, and stem cell transplant are considered.118-121

Patients with type 2 refractory CD are at increased risk to develop T-cell lymphoma.120

New Treatments

It is a need of time to develop non-dietary therapies for CD as about 40% of patients are not satisfied with the only dietary treatment.122 There are recent advances in dietary therapies and few drugs are in the clinical trial phase and the most promising ones are larazotide acetate and gluten-specific proteases ALV003 or latiglutensase.123-125 Larazotide acetate is a zonulin antagonist, an oral peptide designed to tighten adhesions between intestinal cell linings and prevents gluten from crossing the epithelial barrier. It has shown effectiveness in relieving symptoms in patients who are on a gluten-free diet as compared to a placebo plus diet.126 Latiglutensase, an oral mixture of recombinant gluten targeting proteases, targets gluten, breaks it into small fragments before reaching duodenum so in theory to prevent the pathological damage caused by gluten. In a large study done by Murray et al, there was no difference between latiglutensase and placebo in symptoms or histological improvement.124,127 A monoclonal antibody against interleukin-15 and a vaccine called Nexvax2 are currently under investigation.128

Follow-up

Patients diagnosed with CD need close and well-arranged follow-up. Strict adherence to gluten-free diet results in improvement of clinical symptoms in 4 weeks and more than half of the patients’ symptoms resolve completely within 6 months. In serological testing, there is a noticeable decrease in antibody titers after 6 months, so the first follow-up is advised to be scheduled after 6 months of the diagnosis, followed by every 12 to 24 months.97,129 The histological changes take more time to correct, so it is advisable to repeat biopsy after 1 year of treatment and even better if done after 2 years to confirm complete healing.130

Celiac disease is associated with conditions like autoimmune thyroid disease, type 1 diabetes, inflammatory bowel disease, autoimmune hepatitis, autoimmune gastritis, primary biliary sclerosis, and adrenal insufficiency, so physicians need to be vigilant and keep a close eye on these conditions and check anti-nuclear and other organ-specific antibodies during follow-up visits. In newly diagnosed cases, it is recommended to get the basic blood work including complete blood cell count, vitamin B12, folate, vitamin D, calcium level, liver function test, serum albumin, copper, zinc, and vitamin A and E.45,55,79,131

Newly diagnosed adult patients are advised to undergo bone density testing as osteopenia and osteoporosis are very common. It is recommended by the British Society of gastroenterology to measure bone density after 1 year of a
gluten-free diet in patients older than 55 years with other risk factors for osteoporosis.\(^7\) The ones with osteopenia or osteoporosis need calcium and vitamin D replacement and repeat bone scan in 2 years.\(^13\)\(^,\)\(^13\) Celiac disease can present as wide range of clinical symptoms and can be associated with multiple autoimmune conditions. A prompt diagnosis and initiation of treatment carry high importance to prevent associated complications.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**ORCID iD**

Umer Farooq https://orcid.org/0000-0001-8272-0172

**References**

1. Schuppan D. Current concepts of celiac disease pathogenesis. *Gastroenterology*. 2000;119(1):234–242.
2. Kagnoff MF. Celiac disease. A gastrointestinal disease with environmental, genetic, and immunologic components. *Gastroenterol Clin North Am*. 1992;21(2):405–425.
3. Rubio-Tapia A, Ludvigsson JF, Brantner TL, Murray JA, Everhart JE. The prevalence of celiac disease in the United States. *Am J Gastroenterol*. 2012;107(10):1538–1544; quiz 1537.
4. Choung RS, Larson SA, Khaleghi S, et al. Prevalence and morbidity of undiagnosed celiac disease from a community-based study. *Gastroenterology*. 2017;152(4):830–839.
5. Catassi C, Fabiani E, Rätsch IM, et al. The coeliac iceberg in Italy. A multicentre antiagglutin antibodies screening for celiac disease in school-age subjects. *Acta Paediatr Suppl*. 1996;412:29–35.
6. Sher KS, Fraser RC, Wicks Mayberry JF. High risk of coeliac disease in Punjabis. Epidemiological study in the South Asian and European populations of Leicestershire. *Digestion*. 1993;54(3):178–182.
7. Mäki M, Mustalahti K, Kokkonen J, et al. Prevalence of celiac disease among children in Finland. *N Engl J Med*. 2003;348(25):2517–2524.
8. Fasano A, Berti I, Gerarduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. *Arch Intern Med*. 2003;163(3):286–292.
9. Catassi C, Kryszak D, Louis-Jacques O, et al. Detection of Celiac disease in primary care: a multicenter case-finding study in North America. *Am J Gastroenterol*. 2007;102(7):1454–1460.
10. Singh P, Arora S, Lal S, Strand TA, Makharia GK. Risk of celiac disease in the first- and second-degree relatives of patients with celiac disease: a systematic review and meta-analysis. *Am J Gastroenterol*. 2015;110(11):1539–1548.
11. Rubin JE, Crowe SE. Celiac disease. *Ann Intern Med*. 2020;172(1):ITC1–ITC16.
12. Kagnoff MF. Celiac disease: pathogenesis of a model immunogenetic disease. *J Clin Invest*. 2007;117(1):41–49.
13. Fasano A, Catassi C. Clinical practice. *Celiac Disease*. *N Engl J Med*. 2012;367(25):2419–2426.
14. Oxentenko AS, Murray JA. Celiac disease: ten things that every gastroenterologist should know. *Clin Gastroenterol Hepatol*. 2015;13(8):1396–1404; quiz e127–e129.
15. Dominguez Castro P, Harkin G, Hussey M, et al. Changes in presentation of celiac disease in Ireland from the 1960s to 2015. *Clin Gastroenterol Hepatol*. 2017;15(6):864–871.
16. Ludvigsson JF, Leffler DA, Bai JC, et al. The Oslo definitions for coeliac disease and related terms. *Gut*. 2013;62(1):43–52.
17. Leonard MM, Sapone A, Catassi C, Fasano A. Celiac disease and nonceliac gluten sensitivity: a review. *JAMA*. 2017;318(7):647–656.
18. Marsh MN. Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity (“celiac sprue”). *Gastroenterology*. 1992;102(1):330–354.
19. Corazza GR, Villanacci V, Zambelli C, et al. Comparison of the interobserver reproducibility with different histologic criteria used in celiac disease. *Clin Gastroenterol Hepatol*. 2007;5(7):838–843.
20. Oberhuber G, Granditsch G, Vogelsang H. The histopathology of coeliac disease: time for a standardized report scheme for pathologists. *Eur J Gastroenterol Hepatol*. 1999;11(10):1185–1194.
21. Ghosh S. Advances in our understanding of the pathogenesis of celiac disease. *Can J Gastroenterol*. 2011;25(4):186.
22. Shan L, Molberg Ø, Parrot I, et al. Structural basis for gluten intolerance in celiac sprue. *Science*. 2002;297(5590):2275–2279.
23. Matysiak-Budnik T, Moura IC, Arcos-Fajardo M, et al. Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease. *J Exp Med*. 2008;205(1):143–154.
24. Visser J, Rozing J, Sapone A, Lammers K, Fasano A. Tight junctions, intestinal permeability, and autoimmunity: celiac disease and type 1 diabetes paradigms. *Ann N Y Acad Sci*. 2009;1165:195–205.
25. Schumann M, Siegmund B, Schulzke JD, Fromm M. Celiac disease: role of the epithelial barrier. *Cell Mol Gastroenterol Hepatol*. 2017;3(2):150–162.
26. Green PH, Cellier C. Celiac disease. *N Engl J Med*. 2007;357(17):1731–1743.
27. Abadie V, Jabri B. IL-15: a central regulator of celiac disease immunopathology. *Immunol Rev*. 2014;260(1):221–234.
28. Kuja-Halkola R, Lebwohl B, Halfvarson J, Wijmenga C, Magnusson PK, Ludvigsson JF. Heritability of non-HLA genetics in coeliac disease: a population-based study in 107 000 twins. *Gut*. 2016;65(11):1793–1798.
29. Karell K, Louka AS, Moodie SJ, et al. HLA types in celiac disease patients not carrying the DQA1*05-DQB1*02 (DQ2) heterodimer: results from the European Genetics Cluster on Celiac Disease. *Hum Immunol*. 2003;64(4):469–477.
30. Galipeau HJ, McCarville JL, Huebener S, et al. Intestinal microbiota modulates gluten-induced immunopathology in humanized mice. *Am J Pathol*. 2015;185(1):2969–2982.
31. Nistal E, Caminero A, Herrán AR, et al. Study of duodenal bacterial communities by 16S rRNA gene analysis in adults.
with active celiac disease vs non-celiac disease controls. *J Appl Microbiol.* 2016;120(6):1691–1700.

32. Nadal I, Donant E, Ribes-Koninckx C, Calabuig M, Sanz Y. Imbalance in the composition of the duodenal microbiota of children with coeliac disease. *J Med Microbiol.* 2007;56(pt. 12):1669–1674.

33. Nistal E, Camirano A, Vivas S, et al. Differences in faecal bacteria populations and faecal bacteria metabolism in healthy adults and celiac disease patients. *Biochimie.* 2012;94(8):1724–1729.

34. Verdu EF, Galipeau HJ, Jabri B. Novel players in coeliac disease pathogenesis: role of the gut microbiota. *Nat Rev Gastroenterol Hepatol.* 2015;12(9):497–506.

35. Welander A, Tjernberg AR, Montgomery SM, Ludvigsson JF. Infectious disease and risk of later celiac disease in childhood. *Pediatrics.* 2010;125(3):e530–e536.

36. Vriezinga SL, Auricchio R, Bravi E, et al. Randomized feeding intervention in infants at high risk for celiac disease. *N Engl J Med.* 2014;371(14):1304–1315.

37. Aronsson CA, Lee HS, Koletzko S, et al. Effects of gluten intake on risk of celiac disease: a case-control study on a Swedish birth cohort. *Clin Gastroenterol Hepatol.* 2016;14(3):403–409.

38. Szajewska H, Shamir R, Mearin L, et al. Gluten introduction and the risk of celiac disease: a position paper by the European society for pediatric gastroenterology, hepatology, and nutrition. *J Pediatr Gastroenterol Nutr.* 2016;62(3):507–513.

39. Tacik GJ, Verbeek WH, Schreurs MW, Mulder CJ. The spectrum of celiac disease: epidemiology, clinical aspects and treatment. *Nat Rev Gastroenterol Hepatol.* 2010;7(4):204–213.

40. Taylor AK, Lebwohl B, Snyder CL, et al. Celiac disease. In: *GeneReviews®.* Seattle: University of Washington; 1993–2021.

41. Schosler L, Christensen LA, Hvas CL. Symptoms and findings in adult-onset celiac disease in a historical Danish patient cohort. *Scand J Gastroenterol.* 2016;51(3):288–294.

42. Fasano A. Celiac disease—how to handle a clinical chameleon. *Am J Gastroenterol.* 1996;91(10):2099–2102.

43. Sander HW, Magda P, Chin RL, et al. Cerebellar ataxia and coeliac disease. *Lancet.* 2003;362(9395):1548.

44. Ackerman Z, Eliakim R, Stalnikowicz R, Rachmilewitz D. Role of small bowel biopsy in the endoscopic evaluation of adults with iron deficiency anemia. *Am J Gastroenterol.* 1996;91(10):2099–2102.

45. Bushara KO. Neurologic presentation of celiac disease. *Gastroenterology.* 2005;128(4 suppl 1):S92–S97.

46. Caio G, De Giorgio R, Venturi A, et al. Clinical and immunological relevance of anti-neuronal antibodies in celiac disease with neurological manifestations. *Gastroenterology Hepatol Bed Bench.* 2015;8(2):146–152.

47. Sacccone G, Berghella V, Sarro L, et al. Celiac disease and obstetric complications: a systematic review and meta-analysis. *Am J Obstet Gynecol.* 2016;214(2):225–234.

48. Farthing MJ, Edwards CR, Rees LH, Dawson AM. Male gonadal function in coeliac disease: 1. Sexual dysfunction, infertility, and semen quality. *Gut.* 1982;23(7):608–614.

49. Soni S, Badawy SZ. Celiac disease and its effect on human reproduction: a review. *J Reprod Med.* 2010;55(1-2):3–8.

50. Tata LJ, Card TR, Logan RF, Hubbard BB, Smith CJ, West J. Fertility and pregnancy-related events in women with celiac disease: a population-based cohort study. *Gastroenterology.* 2005;128(4):849–855.

51. Tersigni C, Castellani R, de Waure C, et al. Celiac disease and reproductive disorders: meta-analysis of epidemiologic associations and potential pathogenic mechanisms. *Hum Reprod Update.* 2014;20(4):582–593.

52. Ludvigsson JF, Montgomery SM, Ekborn A. Celiac disease and risk of adverse fetal outcome: a population-based cohort study. *Gastroenterology.* 2005;129(2):454–463.

53. Castillo NE, Vanga RR, Theethira TG, et al. Prevalence of abnormal liver function tests in celiac disease and the effect of a gluten-free diet in the US population. *Am J Gastroenterol.* 2015;110(8):1216–1222.

54. Rubio-Tapia A, Murray JA. The liver in celiac disease. *Hepatology.* 2007;46(5):1650–1658.

55. Di Sabatino A, Rosado MM, Cazzola P, et al. Splenic dysfunction and the spectrum of autoimmune and malignant complications in celiac disease. *Clin Gastroenterol Hepatol.* 2006;4(2):179–186.

56. Zone JJ. Skin manifestations of celiac disease. *Gastroenterology.* 2005;128(4 suppl 1):S87–S91.

57. Collin P, Reunala T, Rasmussen M, et al. High incidence and prevalence of adult coeliac disease. Augmented diagnostic approach. *Scand J Gastroenterol.* 1997;32(11):1129–1133.
69. Nieri M, Tofani E, Defraia E, Giuntini V, Franchi L. Enamel defects and aphthous stomatitis in celiac and healthy subjects: systematic review and meta-analysis of controlled studies. J Dent. 2017;65:1–10.

70. Souto-Souza D, da Consolação Soares ME, Rezende VS, de Lacerda Dantas PC, Galvão EL, Falci SGM. Association between developmental defects of enamel and celiac disease: a meta-analysis. Arch Oral Biol. 2018;87:180–190.

71. Kumar S, Gress F, Green PH, Lebwohl B. Chronic pancreatitis is a common finding in celiac patients who undergo endoscopic ultrasound. J Clin Gastroenterol. 2019;53(3):e128–e129.

72. Volta U, Granito A, Fiorini E, et al. Usefulness of antibodies to deamidated gliadin peptides in celiac disease diagnosis and follow-up. Dig Dis Sci. 2008;53(6):1582–1588.

73. Volta U, Molinaro N, de Franceschi L, Fratangelo D, Bianchi FB. IgA anti-endomysial antibodies on human umbilical cord tissue for celiac disease screening. Save both money and monkeys. Dig Dis Sci. 1995;40(9):1902–1905.

74. Sterm M. Comparative evaluation of serologic tests for celiac disease: a European initiative toward standardization. J Pediatr Gastroenterol Nutr. 2000;31(5):513–519.

75. Rubio-Tapia A, Hill ID, Kelly CP, Calderwood AH, Murray JA. American College of Gastroenterology. ACG clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterol. 2013;108(5):656–676; quiz 677.

76. Schyum AC, Rumenssen JJ. Serological testing for celiac disease in adults. United European Gastroenterol J. 2013;1(5):319–325.

77. Zucchini L, Giusti D, Gatoullat G, et al. Interpretation of serological tests in the diagnosis of celiac disease: anti-deamidated gliadin peptide antibodies revisited. Autoimmunity. 2016;49(6):414–420.

78. Amarrí S, Alvisi P, De Giorgio R, et al. Antibodies to deamidated gliadin peptides: an accurate predictor of celiac disease in infancy. J Clin Immunol. 2013;33(5):1027–1030.

79. Ludvigsson JF, Bai JC, Biagi F, et al. Diagnosis and management of adult celiac disease. J Pediatr Gastroenterol Nutr. 2016;63(1):156–165.

80. Catassi C, Fasano A. Celiac disease diagnosis: simple rules are better than complicated algorithms. Am J Med. 2010;123(8):691–693.

81. Bai JC, Ciacci C. World gastroenterology organisation global guidelines: celiac disease February 2017. J Clin Gastroenterol. 2017;51(9):755–768.

82. Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Screening for celiac disease: US preventive services task force recommendation statement. JAMA. 2017;317(12):1252–1257.

83. Egner W, Shrimpton A, Sargur R, Patel D, Swallow K. ESPGHAN guidance on celiac disease 2012: multiples of ULN for decision making do not harmonise assay performance across centres. J Pediatr Gastroenterol Nutr. 2012;55(6):733–735.
107. Ludvigsson JF, Agreus L, Ciacci C, et al. Transition from childhood to adulthood in coeliac disease: the Prague consensus report. *Gut*. 2016;65(8):1242–1251.

108. Mangione RA, Patel PN, Shin E, Fiebert J. Determining the gluten content of nonprescription drugs: information for patients with celiac disease. *J Am Pharm Assoc (2003)* 2011;51(6):734–737.

109. Leffler DA, Edwards-George J, Dennis M, et al. Factors that influence adherence to a gluten-free diet in adults with celiac disease. *Dig Dis Sci*. 2008;53(6):1573–1581.

110. Rubio-Tapia A, Barton SH, Murray JA. Celiac disease and persistent symptoms. *Clin Gastroenterol Hepatol*. 2011;9(1):13–17; quiz e8.

111. Abdulkarim AS, Burgart LJ, See J, Murray JA. Etiology of nonresponsive celiac disease: results of a systematic approach. *Am J Gastroenterol*. 2002;97(8):2016–2021.

112. Rostami K, Kerckhaert J, Tiemessen R, von Blomberg BM, Meijer JW, Mulder CJ. Sensitivity of antiendomysium and antigliadin antibodies in untreated celiac disease: disappointing in clinical practice. *Am J Gastroenterol*. 1999;94(4):888–894.

113. Leffler DA, Dennis M, Hyett B, Kelly E, Schuppan D, Kelly CP. Etiologies and predictors of diagnosis in nonresponsive celiac disease. *Clin Gastroenterol Hepatol*. 2007;5(4):445–450.

114. Stasi E, Marafini I, Caruso R, et al. Frequency and cause of persistent symptoms in celiac disease patients on a long-term gluten-free diet. *J Clin Gastroenterol*. 2016;50(3):239–243.

115. Rubio-Tapia A, Murray JA. Classification and management of refractory coeliac disease. *Gut*. 2010;59(4):547–557.

116. Cellier C, Delabesse E, Helmer C, et al. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group. *Lancet*. 2000;356(9225):203–208.

117. Malamut G, Afchian P, Verkarre V, et al. Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. *Gastroenterology*. 2009;136(1):81–90.

118. van Gils T, Nijboer P, van Wanrooij RL, Bouma G, Mulder CJ. Mechanisms and management of refractory coeliac disease. *Nat Rev Gastroenterol Hepatol*. 2015;12(10):572–579.

119. Mukewar SS, Sharma A, Rubio-Tapia A, Wu TT, Jabri B, Murray JA. Open-capsule budesonide for refractory celiac disease. *Am J Gastroenterol*. 2017;112(6):959–967.

120. Rubio-Tapia A, Kelly DG, Lahr Dogan A, Wu TT, Murray JA. Clinical staging and survival in refractory celiac disease: a single center experience. *Gastroenterology*. 2009;136(1):99–107; quiz 352.

121. Rishi AR, Rubio-Tapia A, Murray JA. Refractory celiac disease. *Expert Rev Gastroenterol Hepatol*. 2016;10(4):537–546.

122. Aziz I, Evans KE, Papageorgiou V, Sanders DS. Are patients with celiac disease seeking alternative therapies to a gluten-free diet. *J Gastrointestin Liver Dis*. 2011;20(1):27–31.

123. Leffler DA, Kelly CP, Green PH, et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. *Gastroenterology*. 2015;148(7):1311–1319.

124. Lähdeaho ML, Kaukinen K, Laurila K, et al. Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease. *Gastroenterology*. 2014;146(7):1649–1658.

125. Gottlieb K, Dawson J, Hussain F, Murray JA. Development of drugs for celiac disease: review of endpoints for Phase 2 and 3 trials. *Gastroenterol Rep (Oxf)*. 2015;3(2):91–102.

126. Ludvigsson JF, Ciacci C, Green PH, et al. Outcome measures in celiac disease trials: the Tampere recommendations. *Gut*. 2018;67(8):1410–1424.

127. Murray JA, Kelly CP, Green PHR, et al. No difference between latiglutenase and placebo in reducing villous atrophy or improving symptoms in patients with symptomatic celiac disease. *Gastroenterology*. 2017;152(4):787–798.

128. Tuitt KE, Daveson AJM, Ee HC, et al. Randomised clinical trial: a placebo-controlled study of subcutaneous or intradermal NEXVAX2, an investigational immunomodulatory peptide therapy for coeliac disease. *Aliment Pharmacol Ther*. 2019;50(5):547–555. doi:10.1111/apt.15435.

129. Sugai E, Nachman F, Váquez H, et al. Dynamics of celiac disease-specific serology after initiation of a gluten-free diet and use in the assessment of compliance with treatment. *Dig Liver Dis*. 2010;42(5):352–358.

130. Rubio-Tapia A, Rahim MW, See JA, Lahr BD, Wu TT, Murray JA. Mucosal recovery and mortality in adults with celiac disease after treatment with a gluten-free diet. *Am J Gastroenterol*. 2010;105(6):1412–1420.

131. Pietzak MM. Follow-up of patients with celiac disease: achieving compliance with treatment. *Gastroenterology*. 2005;128(4 suppl 1):S135–S141.

132. Meyer D, Stavropolous S, Diamond B, Shane E, Green PH. Osteoporosis in a North American adult population with celiac disease. *Am J Gastroenterol*. 2001;96(1):112–119.

133. Duersken D, Pinto-Sanchez MI, Anca A, et al. Management of bone health in patients with celiac disease: practical guide for clinicians. *Can Fam Physician*. 2018;64(6):433–438.